In this article
Eli Lilly
on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business. The pharmaceutical giant also expects its adjusted fiscal 2025 earnings to come in between $21.75 to $23, up from a previous guidance of $20.78 and $22.28 per share.
Eli Lilly said the guidance does not include President Donald Trump’s planned tariffs on pharmaceuticals imported into the U.S.
